Chotosan, a kampo formula, ameliorates hippocampal LTD and cognitive deficits in juvenile-onset diabetes rats

Journal of Pharmacological Sciences

Volumn 124, Issue 2, 2014, Pages 192-200

  Sasaki Hamada, Sachie ^a   Tamaki, Keita ^a   Otsuka, Hayuma ^a   Ueno, Tatsuto ^a   Sacai, Hiroaki ^a   Niu, Yimin ^b   Matsumoto, Kinzo ^b   Oka, Jun Ichiro ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Chotosan; Hippocampal synaptic plasticity; NR2B subunit; Streptozotocin induced diabetes; Working memory

Indexed keywords

AMPA RECEPTOR; CHOTOSAN; KAMPO; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM DEPRESSION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SPATIAL MEMORY; SYNAPTIC TRANSMISSION; WORKING MEMORY;

ANIMALS; COGNITION DISORDERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; LONG-TERM SYNAPTIC DEPRESSION; MALE; MEDICINE, KAMPO; MEMORY; PHYTOTHERAPY; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RISK; STREPTOZOCIN;

EID: 84895558377     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13179FP     Document Type: Article

References (37)

1. Terasawa K, Shimada Y, Kita T, Yamamoto T, Tosa H, Tanaka N, et al. Choto-san in the treatment of vascular dementia: a double-blind, placebo-controlled study. Phytomedicine. 1997;4: 15-22.
2. Zhao Q, Murakami Y, Tohda M, Obi R, Shimada Y, Matsumoto K. Chotosan, a kampo formula, ameliorates chronic cerebral hypoperfusion-induced deficits in object recognition behaviors and central cholinergic systems in mice. J Pharmacol Sci. 2007;103: 360-373.
3. Zhao Q, Murakami Y, Tohda M, Watanabe H, Matsumoto K. Preventive effect of chotosan, a Kampo medicine, on transient ischemia-induced learning deficit is mediated by stimulation of muscarinic M1 but not nicotinic receptor. Biol Pharm Bull. 2005;28: 1873-1878.
4. Matsumoto K, Zhao Q, Niu Y, Fujiwara H, Tanaka K, Sasaki-Hamada S, et al. Kampo formulations, Chotosan, and Yokukansan, for dementia therapy: existing clinical and preclinical evidence. J Pharmacol Sci. 2013:122: 257-269.
5. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev. 2008;29: 494-511.
6. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care. 2005;28: 726-735.
7. Sachon C, Grimaldi A, Digy JP, Pillon B, Dubois B, Thervet F. Cognitive function, insulin-dependent diabetes and hypoglycaemia. J Intern Med. 1992; 231: 471-475.
8. Ryan CM, Williams TM, Finegold DN, Orchard TJ. Cognitive dysfunction in adults with type 1 (insulin-dependent) diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia. 1993;36: 329-334.
9. Ferguson SC, Blane A, Wardlaw J, Frier BM, Perros P, McCrimmon RJ, et al. Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care. 2005;28: 1431-1437.
10. Gaudieri PA, Chen R, Greer TF, Holmes CS. Cognitive function in children with type 1 diabetes: a meta-analysis. Diabetes Care. 2008;31: 1892-1897.
11. Lin A, Northam EA, Rankins D, Werther GA, Cameron FJ. Neuropsychological profiles of young people with type 1 diabetes 12 yr after disease onset. Pediatr Diabetes. 2010;11: 235-243.
12. Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, et al. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes. 1996;45: 1259-1266.
13. Artola A, Kamal A, Ramakers GM, Biessels GJ, Gispen WH. Diabetes mellitus concomitantly facilitates the induction of long-term depression and inhibits that of long-term potentiation in hippocampus. Eur J Neurosci. 2005;22: 169-178.
14. Stranahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM, Mattson MP. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci. 2008;11: 309-317.
15. Iwai T, Suzuki M, Kobayashi K, Mori K, Mogi Y, Oka J-I. The influence of juvenile diabetes on memory and hippocampal plasticity in rats: improving effects of glucagon-like peptide-1. Neurosci Res. 2009;64: 67-74.
16. Sasaki-Hamada S, Sacai H, Oka J-I. Diabetes onset influences hippocampal synaptic plasticity in streptozotocin-induced rats. Neuroscience. 2012;227: 293-304.
17. Collingridge GL, Peineau S, Howland JG, Wang YT. Long-term depression in the CNS. Nat Rev Neurosci. 2012;11: 459-473.
18. Zhao Q, Niu Y, Matsumoto K, Tsuneyama K, Tanaka K, Miyata T, et al. Chotosan ameliorates cognitive and emotional deficits in an animal model of type2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain. BMC Complement Altern Med. 2012;12:188.
19. Sugiyama A, Saitoh A, Iwai T, Takahashi K, Yamada M, Sasaki-Hamada S, et al. Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines. Neuropharmacology. 2012;62: 2489-2498.
20. Hayashi H, Tohda M, Watanabe H, Murakami Y, Matsumoto K. The effects of Choto-san on the mRNA expression of Alzheimer's disease related factors in the permanent ischemic rat brain. Biol Pharm Bull. 2005;28: 744-746.
21. Katz B, Miledi R. The role of calcium in neuromuscular facilitation. J Physiol. 1968;195: 481-492.
22. Zucker RS. Short-term synaptic plasticity. Annu Rev Neurosci. 1989;12: 13-31.
23. Conrad CD, Galea LA, Kuroda Y, McEwen BS. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav Neurosci. 1996;110: 1321-1334.
24. Murakami Y, Zhao Q, Harada K, Tohda M, Watanabe H, Matsumoto K. Choto-san, a Kampo formula, improves chronic cerebral hypoperfusion-induced spatial learning deficit via stimulation of muscarinic M1 receptor. Pharmacol Biochem Behav. 2005;81: 616-625.
25. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973;232: 331-356.
26. Bliss TV, Collingridge GL. Role of distinct NMDA receptor subtypes at central synapses. Nature. 1993;361: 31-39.
27. Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001;294: 1030-1038.
28. Isaac JT, Lüthi A, Palmer MJ, Anderson WW, Benke TA, Collingridge GL. An investigation of the expression mechanism of LTP of AMPA receptor-mediated synaptic transmission at hippocampal CA1 synapses using failures analysis and dendritic recordings. Neuropharmacology. 1998;37: 1399-1410.
29. Castellano C, Cestari V, Ciamei A. NMDA receptors and learning and memory processes. Curr Drug Targets. 2001;23: 273-283.
30. Kang TH, Murakami Y, Matsumoto K, Takayama H, Kitajima M, Aimi N, et al. Rhynchophylline and isorhynchophylline inhibit NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2002;455: 27-34.
31. Zhao Q, Yokozawa T, Tsuneyama K, Tanaka K, Miyata T, Shibahara N, et al. Chotosan (Diaoteng San)-induced improvement of cognitive deficits in senescence-accelerated mouse (SAMP8) involves the amelioration of angiogenic/neurotrophic factors and neuroplasticity systems in the brain. Chin Med. 2011;6:33.
32. Lei S, Lu WY, Xiong ZG, Orser BA, Valenzuela CF, MacDonald JF. Platelet-derived growth factor receptor-induced feed-forward inhibition of excitatory transmission between hippocampal pyramidal neurons. J Biol Chem. 1999;274: 30617-30623.
33. Sanger DJ, Joly D. Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice. Psychopharmacology. 1991;104: 27-34.
34. Okiyama K, Smith DH, White WF, Richter K, McIntosh TK. Effects of the novel NMDA antagonists CP-98, 113, CP-101, 581 and CP-101, 606 on cognitive function and regional cerebral edema following experimental brain injury in the rat. J Neurotrauma. 1997;14: 211-222.
35. Doyle KM, Feerick S, Kirkby DL, Eddleston A, Higgins GA. Comparison of various N-methyl-D-aspartate receptor antagonists in a model of short-term memory and on overt behaviour. Behav Pharmacol. 1998;9: 671-681.
36. Higgins GA, Ballard TM, Huwyler J, Kemp JA, Gill R. Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology. 2003;44: 324-341.
37. Guscott MR, Clarke HF, Murray F, Grimwood S, Bristow LJ, Hutson PH. The effect of (+/-)-CP-101, 606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. Eur J Pharmacol. 2003;476: 193-199.